Johns Hopkins University Researchers To Clinically Assess Rosetta Genomics’ MiRview(TM) Squamous Assay
Oct 3rd 2008Drug InformationClinical Trials
Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today the initiation of a clinical assessment study with the Johns Hopkins University School of Medicine. The study will compare Rosetta Genomics’ miRview(TM) squamous, which differentiates squamous from non squamous non small cell lung cancer, with available immunohistochemistry methods.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
